Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 analogue added to birch pollen SCIT in allergic rhinitis
NL-OMON46004Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing SCIT + Zemplar with SCIT + placebo (2 arms). Primary endpoint: IL-10 production by PBMCs after allergen-specific stimulation at week 5. Started Sep 2018; status: active, not recruiting.
02
Drugs
paricalcitolalutard-sq
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NL-OMON46004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46004.